Advertisement
Advertisement
U.S. markets open in 2 hours 56 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Nuwellis, Inc. (NUWE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.90+1.23 (+16.04%)
At close: 04:00PM EST
10.00 +1.10 (+12.36%)
Pre-Market: 06:30AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close7.67
Open7.78
Bid0.00 x 1300
Ask0.00 x 2200
Day's Range7.53 - 10.89
52 Week Range6.08 - 185.00
Volume3,090,907
Avg. Volume392,670
Market Cap4.774M
Beta (5Y Monthly)0.31
PE Ratio (TTM)N/A
EPS (TTM)-2.17
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est113.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NUWE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Nuwellis, Inc.
    Analyst Report: Danaher Corp.Danaher is a diversified life sciences and diagnostics company with global operations. In March 2020, it acquired the GE Biopharma business and renamed it Cytiva. Danaher has continued to make acquisitions, including Aldevron in 2021, that strengthen its technology and manufacturing capabilities.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

    MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be approximately $2.3 million and $8.5 million, respectively, representing an increase of 42% and 8% over the same periods

  • GlobeNewswire

    Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer

    Dr. Jefferies brings over two decades of cardiology and heart failure expertise to Nuwellis as the Company expands clinical evidence supporting the use of ultrafiltration for people with fluid overloadMINNEAPOLIS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of John Jefferies, MD, MPH, FACC, FHFSA as Chief Medical Officer (CMO). In this new role, Dr. J

  • GlobeNewswire

    Nuwellis, Inc. Announces Passage of Warrant Proposal

    MINNEAPOLIS, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company held its adjourned special meeting of stockholders on January 4, 2023 at 2:00 p.m. (Central Time) (the “Special Meeting”). At the time of the Special Meeting, stockholders (i) approved the Warrant Proposal (as defined below) and (ii) authorized one or more adjournments of the meeting of stockho

Advertisement
Advertisement